African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development

EBioMedicine

Volumn 17, Issue , 2017, Pages 67-74

  Rajman, Iris ^a   Knapp, Laura ^b   Morgan, Thomas ^c   Masimirembwa, Collen ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b OXFORD PHARMAGENESIS LTD   (United Kingdom)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d African Institute of Biomedical Science and Technology   (Zimbabwe)

Author keywords

Africa; CYP450; Drug development; Drug metabolism; Genetic diversity; Pharmacogenetics

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME;

AFRICA; ALLELE; ANCESTRY GROUP; ARTICLE; DNA POLYMORPHISM; DRUG METABOLISM; ETHNICITY; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; BLACK PERSON; DRUG DEVELOPMENT; GENETIC POLYMORPHISM; GENETICS; META ANALYSIS;

AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; GENE FREQUENCY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 85013407962     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.02.017     Document Type: Article

References (50)

1. Alessandrini, M., Pepper, M.S., Priority pharmacogenetics for the African continent: focus on CYP450. Pharmacogenomics 15 (2014), 385–400.
2. Ampadu, H.H., Hoekman, J., De Bruin, M.L., Pal, S.N., Olsson, S., Sartori, D., Leufkens, H.G., Dodoo, A.N., Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 39 (2016), 335–345.
3. Bains, R.K., Kovacevic, M., Plaster, C.A., Tarekegn, A., Bekele, E., Brandman, N.N., Thomas, M.G., Molecular diversity and population structure at the cytochrome p450 3A5 gene in Africa. BMC Genet. 14 (2013), 1–18.
4. Bell, G.C., Caudle, K.E., Whirl-Carillo, M., Gordon, R.J., Hikino, K., Prows, C.A., Gaedigk, A., Agundez, J.A., Sadhasivam, S., Klein, T.E., Schwab, M., Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the CYP2D6 genotype and use of ondansetron and tropisetron. Clin. Pharmacol. Ther., 2016, 10.1002/cpt.598 (Epub ahead of print).
5. Birdwell, K.A., Decker, B., Barbarino, J.M., Peterson, J.F., Stein, C.M., Sadee, W., Wang, D., Vinks, A.A., He, Y., Swen, J.J., Leeder, J.S., Van Schaik, R., Thummel, K.E., Klein, T.E., Caudle, K.E., Macphee, I.A., Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther., 98, 2015.
6. Caudle, K.E., Dunnenberger, H.M., Freimuth, R.R., Peterson, J.F., Burlison, J.D., Whirl-Carillo, M., Scott, S.A., Rehm, H.L., Williams, M.S., Klein, T.E., Relling, M.V., Hoffman, J.M., Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet. Med., 2016, 10.1038/gim.2016.87 (Epub ahead of print).
7. Chen, L., Qin, S., Xie, J., Tang, J., Yang, L., Shen, W., Zhao, X., He, G., Feng, G., He, L., Xing, Q., Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographical areas of mainland China. Pharmacogenomics 9 (2008), 691–702.
8. Čolić, A., Alessandrini, M., Pepper, M.S., Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine. Drug Metab. Rev. 47 (2014), 111–123.
9. Crews, K.R., Gaedigk, A., Dunnenberger, H.M., Klein, T.E., Shen, D.D., Callaghan, J.T., Kharasch, E.D., Skaar, T.C., Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91 (2012), 321–326.
10. Dean, L., Tamoxifen therapy and CYP2D6 genotype. Medical Genetics Summaries, 2016, National Center for Biotechnology Information (US); 2012, Bethesda (MD) Internet. Available from: https://www.ncbi.nlm.nih.gov/books/NBK61999/.
11. Dickmann, L.J., Rettie, A.E., Kneller, B.M., Kim, R.B., Wood, A.J.J., Stein, C.M., Wilkinson, G.R., Schwarz, U.I., Identification and functional charactertization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol. 60 (2001), 382–387.
12. di Iulio, J., Fayet, A., Arab-Alameddine, M., Rotget, M., Lubomirov, R., Cavassini, M., Furrer, H., Günthard, H.F., Colombo, S., Csajka, C., Eap, C.B., Decosterd, L.A., Telenti, A., the Swiss HIV Cohort Study, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19 (2009), 300–309.
13. Dodgen, T.M., Hochfeld, W.E., Fickl, H., Asfaha, S.M., Durandt, C., Rheeder, P., Drögemöller, B.I., Wright, G.B., Warnich, L., Labuschagne, C.D.J., van Schalkwyk, A., Gaedigk, A., Pepper, M.S., Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparitive prospective cohort study. BMC Med. Genet. 14 (2013), 20–35.
14. Drögemöller, B.I., Wright, G.E., Niehaus, D.J., Koen, L., Malan, S., Da Silva, D.M., Hillerman-Rebello, R., La Grange, A.M., Venter, M., Warnich, L., Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 11 (2010), 1095–1103.
15. Fujikara, K., Ingelman-Sundberg, M., Lauschke, V.M., Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet. Genomics 25 (2015), 584–594.
16. Gaedigk, A., Coetsee, C., The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur. J. Clin. Pharmacol. 64 (2008), 465–475.
17. Gaedigk, A., Sangkuhl, K., Whirl-Carillo, M., Klein, T., Leeder, J.S., Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine 19 (2016), 69–76.
18. Gurdasani, D., Carstensen, T., Tekola-Ayele, F., Pagani, L., Tachmazidou, I., Hatzikotoulas, K., Karthikeyan, S., Iles, L., Pollard, M.O., Choudury, A., Ritchie, G.R., Xue, Y., Asimit, J., Nsubuga, R.N., Young, E.H., Pomilla, C., Kivenen, K., Rockett, K., Kamali, A., Doumatey, A.P., Asiki, G., Seeley, J., Sisay-Joof, F., Jallow, M., Tollman, S., Meknonnen, E., Ekong, R., Oljira, T., Bradman, N., Bojang, K., Ramsay, M., Adeyemo, A., Bekele, E., Motala, A., Norris, S.A., Pirie, F., Kaleebu, P., Kwiatkowski, D., Tyler-Smith, C., Rotimi, C., Zeggini, E., Sandhu, M.S., The African Genome Variation Project shapes medical genetics in Africa. Nature 517 (2015), 327–332.
19. Hicks, J.K., Bishop, J.R., Sangkuhl, K., Ji, Y., Leckband, S.G., Leeder, J.S., Graham, R.L., Chiulli, D.L., Llerena, A., Skaar, T.C., Scott, S.A., Stingl, J.C., Klein, T.E., Caudle, K.E., Gaedigk, A., Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98 (2015), 127–134.
20. Hicks, J.K., Sangkuhl, K., Swen, J.J., Ellingrod, V.L., Müller, D.J., Shimoda, K., Bishop, J.R., Kharasch, E.D., Skaar, T.C., Gaedigk, A., Dunnenberger, H.M., Klein, T.E., Caudle, K.E., Stingl, J.C., Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther., 2016, 10.1002/cpt.597 (Epub ahead of print).
21. Hicks, J.K., Swen, J.J., Thorn, C.F., Sangkuhl, K., Kharasch, E.D., Ellingrod, V.L., Skaar, T.C., Müller, D.J., Gaedigk, A., Stingl, J.C., Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93 (2013), 402–408.
22. Ingeman-Sundberg, M., Sim, S.C., Gomez, A., Rodriguez-Antona, C., Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116 (2007), 496–526.
23. Iyun, A.O., Lennard, M.S., Tucker, G.T., Woods, H.F., Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin. Pharmacol. Ther. 40 (1986), 389–394.
24. Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.H., Eichelbaum, M., Schwab, M., Zanger, U.M., Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15 (2005), 861–873.
25. Kozyra, M., Ingeman-Sundberg, M., Lauschke, V.M., Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet. Med., 2016, 10.1038/gim.2016.33.
26. Leathart, J.B., London, S.J., Steward, A., Adams, J.D., Idle, J.R., Daly, A.K., CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8 (1998), 529–541.
27. Lee, S.Y., Sohn, K.M., Ryu, J.Y., Yoon, Y.R., Shin, J.G., Kim, J.W., Sequence-based CYP2D6 genotyping in the Korean population. Ther. Drug Monit. 28 (2006), 382–387.
28. Li, X.Q., Bjorkman, A., Andersson, T.B., Ridderstrom, M., Masimirembwa, C.M., Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300 (2002), 399–407.
29. Mardis, E.R., DNA sequencing technologies: 2006–2016. Nat. Protoc. 12 (2017), 213–218.
30. Masimirembwa, C., Persson, I., Bertilsson, L., Hasler, J., Ingeman-Sundberg, M., A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol. 42 (1996), 713–719.
31. Mbanefo, C., Bababunmi, E.A., Mahgoub, A., Sloan, T.P., Idle, J.R., Smith, R.L., A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 10 (1980), 811–818.
32. Mizutani, T., PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 35 (2003), 99–106.
33. Mulder, N.J., Adebiyi, E., Alami, R., Benkahla, A., Brandful, J., Doumbia, S., Everett, D., Fadlelmola, F.M., Gaboun, F., Gaseitsiwe, S., Ghazal, H., Hazelhurst, S., Hide, W., Ibrahimi, A., Fakim, Y.J., Jongeneel, V.C., Joubert, F., Kassim, S., Kayondo, J., Kumuthini, J., Lyantagaye, S., Makani, J., Alzohairy, A.M., Masiga, D., Moussa, A., Nash, O., Oukem-Boyer, O.O.M., Owusu-Dabo, E., Panji, S., Patterton, H., Radouani, F., Sadki, K., Seghrouchni, F., Bishop, O.T., Tiffin, N., Ulenga, N., The H3ABioNet Consortium, H3ABioNet, a sustainable, pan-African bioinformatics network for human heredity and health in Africa. Genome Res. 26 (2016), 271–277.
34. Murray, C.J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J.A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn, S.Y., Ali, M.K., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson, C., Baddour, L.M., Bahalim, A.N., Barker-Collo, S., Barrero, L.H., Bartels, D.H., Basanez, M.G., Baxter, A., Bell, M.L., Menjamin, E.J., Bennett, D., Brnabe, E., Bhalla, K., Bhandari, B., Bikbov, B., Bin Abdulhak, A., Birbeck, G., Black, J.A., Blencowe, H., Blore, J.D., Blyth, F., Bolliger, I., Bonaventure, A., Boufous, S., Bourne, R., Boussinesq, M., Braithwaite, T., Brayne, C., Bridgett, L., Brooker, S., Brooks, P., Brugha, T.S., Bryan-Hancock, C., Bucello, C., Buchbinder, R., Buckle, G., Budke, C.M., Burch, M., Burney, P., Burstein, R., Calabria, B., Campbell, B., Canter, C.E., Carabin, H., Carapetis, J., Carmona, L., Cella, C., Charlson, F., Chen, H., Cheng, A.T., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., Colquhoun, S., Colson, K.E., Condon, J., Connor, M.D., Cooper, L.I., Corriere, M., Cortinovis, M., de Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.M., Cross, M., Dabhadkar, K.C., Dahiya, M., Dahodwala, N., Damsere-Derry, J., Danaei, G., Davis, A., de Leo, D., Degenhardt, L., Dellavalle, R., Delossantos, A., Denenberg, J., Derrett, S., Des Jarlais, D.C., Dharmaratne, S.D., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2197–2223.
35. Myrand, S.P., Sekiguchi, K., Man, M.Z., Lin, X., Tzeng, R.Y., Teng, C.H., Hee, B., Garrett, M., Kikkawa, H., Lin, C.Y., Eddy, S.M., Dostalik, J., Mount, J., Azuma, J., Fujio, Y., Jang, I.J., Shin, S.G., Bleavins, M.R., Williams, J.A., Paulauskis, J.D., Wilner, K.D., Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther. 84 (2008), 347–361.
36. Ng, D., Hong, C.S., Singh, L.N., Johnston, J.J., Mullikin, J.C., Biesecker, L.G., Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening. Genet. Med., 2016, 10.1038/gim.2016.105 (Epub ahead of print).
37. Parikh, S., Ouedaogo, J.B., Goldstein, J.A., Rosenthal, P.J., Kroetz, D.L., Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin. Pharmacol. Ther. 82 (2007), 197–203.
38. Park, S.Y., Kang, Y.S., Jeong, M.S., Yoon, H.K., Han, K.O., Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J. Clin. Pharm. Ther. 33 (2008), 61–65.
39. Prentis, R.A., Lis, Y., Walker, S.R., Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985). Br. J. Clin. Pharmacol. 25 (1988), 387–396.
40. Radloff, R., Gras, A., Zanger, U.M., Masquelier, C., Arumugam, K., Karasi, J.C., Arendt, V., Seguin-Devaux, C., Klein, K., Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools. Hum. Mutat. 34 (2013), 725–734.
41. Shankar, P.R., VigiAccess: promoting public access to VigiBase. Indian J. Pharmacol. 48 (2016), 606–607.
42. Sommers, D.K., Moncrieff, J., Avenant, J., Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa. Hum. Toxicol. 7 (1988), 273–276.
43. Sommers, D.K., Moncrieff, J., Avenant, J., Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa. Hum. Toxicol. 8 (1989), 39–43.
44. Suarez-Kurtz, G., Paula, D.P., Struchiner, C.J., Pharmacogenomic implications of population admixture: Brazil as a model case. Pharmacogenomics 15 (2014), 209–219.
45. Tishkoff, S.A., Reed, F.A., Friedlaender, F.R., Ehret, C., Ranciaro, A., Froment, A., Hirbo, J.B., Awomoyi, A.A., Bodo, J.M., Doumbo, O., Ibrahim, M., Juma, A.T., Kotze, M.J., Lema, G., Moore, J.H., Mortenesen, H., Nyambo, T.B., Omar, S.A., Powell, K., Pretorius, G.S., Smith, M.W., Thera, M.A., Wambebe, C., Weber, J.L., Williams, S.M., The genetic structure and history of Africans and African Americans. Science 324 (2009), 1035–1044.
46. Wright, G.E.B., Niehaus, D.J.H., Drögemöller, B.I., Koen, L., Gaedigk, A., Warnich, L., Elucidation of CYP2D6 genetic diversity in a unique African populations: implications for the future application of pharmacogenetics in the Xhosa population. Ann. Hum. Genet. 74 (2010), 340–350.
47. Wright, G.E., Koornhof, P.G., Adeyemo, A.A., Tiffin, N., Ethical and legal implications of whole genome and whole exome sequencing in African populations. BMC Med. Ethics 14 (2013), 21–36.
48. Wright, G.E.B., Carleton, B., Hayden, M.R., Ross, C.J.D., The global spectrum of protein-coding pharmacogenomic diversity. Pharmacogenomics J., 2016, 10.1038/tpj.2016.77.
49. Xiong, Y., Wang, M., Fang, K., Xing, Q., Feng, G., Shen, L., He, L., Qin, S., A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics 97 (2011), 227–281.
50. Yang, W., Wu, G., Broeckel, U., Smith, C.A., Turner, V., Haidar, C.E., Wang, S., Carter, R., Karol, S.E., Neale, G., Crews, K.R., Yang, J.J., Mullighan, C.G., Downing, J.R., Evans, W.E., Relling, M.V., Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clin. Pharmacol. Ther. 100 (2016), 360–368.